NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
MaxCyte, Inc. MXCT
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$33.0M
▼ 14.5% vs FY2024
EPS · FY25
$-0.42
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-23.6%
Net margin · FY25
-135.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 33.0M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 135 cents on every revenue dollar this year.
Per share
USD -0.42
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-23.6%
Return on equity, FY2025
ROE
Operating margin-157.1%
Net margin-135.1%
Return on assets-20.2%
Each USD of equity lost 24 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+4.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−9.3%
+4.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.11B
Shares outstanding, FY2025
Change, 5 years+38.0%
Change, 10 years—
The share count grew 38% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 202.5M
total assets, end of FY2025
Total assetsUSD 202.5M
EquityUSD 171.5M
CashUSD 20.1M
Current ratio8.30×
Equity funds 85% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.42
−0.39
−0.37
−0.23
−0.21
−0.17
−0.23
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−23.6
−18.7
−15.6
−9.1
−12.9
−50.5
−94.8
Shares out B
0.11
0.11
0.10
0.10
0.10
0.08
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 26
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed